-
11 Comments
AbbVie Inc is currently in a long term uptrend where the price is trading 10.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.9.
AbbVie Inc's total revenue rose by 59.2% to $14B since the same quarter in the previous year.
Its net income has dropped by 98.7% to $36M since the same quarter in the previous year.
Finally, its free cash flow grew by 47.0% to $5B since the same quarter in the previous year.
Based on the above factors, AbbVie Inc gets an overall score of 4/5.
Bull Pen Trades
Follow
3 years, 3 months ago
|
TradeWithAlerts
Follow
3 years, 3 months ago
|
WALL ST JESUS
Follow
3 years, 3 months ago
|
Brad Scruggs
Follow
3 years, 3 months ago
|
TradeWithAlerts
Follow
3 years, 3 months ago
|
Industry | Drug Manufacturers-General |
---|---|
Sector | Healthcare |
CurrencyCode | USD |
Exchange | NYSE |
ISIN | US00287Y1091 |
Beta | 0.59 |
---|---|
Dividend Yield | 3.5% |
Market Cap | 287B |
Target Price | 164.22 |
PE Ratio | 24.5 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ABBV using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024